BrightSpring Health Services (NASDAQ:BTSG) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of BrightSpring Health Services (NASDAQ:BTSG) from a buy rating to a strong-buy rating in a research note released on Saturday,Wall Street Zen reports.

A number of other research firms have also recently commented on BTSG. UBS Group increased their price target on shares of BrightSpring Health Services from $63.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Wells Fargo & Company boosted their price objective on shares of BrightSpring Health Services from $61.00 to $78.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Zacks Research cut BrightSpring Health Services from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. Morgan Stanley increased their target price on BrightSpring Health Services from $71.00 to $80.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. Finally, KeyCorp reissued an “overweight” rating on shares of BrightSpring Health Services in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, BrightSpring Health Services currently has an average rating of “Moderate Buy” and an average target price of $77.62.

BrightSpring Health Services Stock Performance

Shares of BTSG stock opened at $66.26 on Friday. The company has a market capitalization of $13.11 billion, a price-to-earnings ratio of 35.82, a price-to-earnings-growth ratio of 0.77 and a beta of 1.87. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.22 and a current ratio of 1.59. BrightSpring Health Services has a one year low of $30.64 and a one year high of $73.75. The company’s 50-day moving average is $60.09 and its 200 day moving average is $54.68.

BrightSpring Health Services (NASDAQ:BTSG) last issued its earnings results on Friday, October 30th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.07. The business had revenue of $4.21 billion during the quarter, compared to analysts’ expectations of $3.88 billion. BrightSpring Health Services had a net margin of 2.55% and a return on equity of 16.73%. The firm’s revenue for the quarter was up 26.4% compared to the same quarter last year. Sell-side analysts expect that BrightSpring Health Services will post 1.64 EPS for the current fiscal year.

Hedge Funds Weigh In On BrightSpring Health Services

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Calamos Advisors LLC purchased a new stake in shares of BrightSpring Health Services during the 3rd quarter valued at about $1,303,000. Kraematon Investment Advisors Inc. purchased a new stake in shares of BrightSpring Health Services during the 3rd quarter valued at about $211,000. Kestra Advisory Services LLC bought a new position in shares of BrightSpring Health Services in the 3rd quarter worth approximately $206,000. Bridge City Capital LLC bought a new position in shares of BrightSpring Health Services in the 3rd quarter worth approximately $4,057,000. Finally, Aviance Capital Partners LLC lifted its stake in shares of BrightSpring Health Services by 33.3% in the 3rd quarter. Aviance Capital Partners LLC now owns 8,000 shares of the company’s stock worth $454,000 after purchasing an additional 2,000 shares during the period.

BrightSpring Health Services News Roundup

Here are the key news stories impacting BrightSpring Health Services this week:

• Positive Sentiment: Strong Q3 performance and higher guidance: BrightSpring’s third-quarter earnings reportedly rose 80%, with pharmacy and home health growth driving a revenue beat and margin expansion. Management also raised its 2026 outlook and highlighted potential for continued organic growth in 2027, supported by specialty drug launches and home health gains. BrightSpring Q3 Earnings Beat on Specialty Growth, 2026 View Raised
• Positive Sentiment: Analysts raised price targets: Leerink Partners increased its target from $72 to $92 and assigned an “outperform” rating. TD Cowen raised its target from $81 to $84 and issued a “buy” rating, while Wells Fargo lifted its target from $78 to $82 and maintained an “overweight” rating. These revisions signal increased confidence in BrightSpring’s earnings growth and business momentum. Leerink Partners BrightSpring Ratings TD Cowen BrightSpring Ratings Wells Fargo BrightSpring Ratings
• Positive Sentiment: Improved consensus sentiment: Wall Street Zen upgraded BTSG to “strong-buy,” adding to the favorable analyst commentary surrounding the earnings report. Wall Street Zen Upgrades BrightSpring to Strong-Buy

BrightSpring Health Services Company Profile

BrightSpring Health Services (NASDAQ:BTSG) is a Louisville, Kentucky-based provider of home- and community-based health services and pharmacy services. The company focuses on supporting individuals with complex or chronic care needs, including older adults and people with disabilities, through care delivered in homes, communities and other non-hospital settings.

Its services include home health, hospice, personal care, behavioral health, primary care, rehabilitation and community living programs.